local_hospital

Centrum Medyczno- Diagnostyczne Sp. z o.o.

Address
lock Available on a paid plan

Centrum Medyczno-Diagnostyczne Sp. z o.o.

Centrum Medyczno-Diagnostyczne is a specialized medical research facility dedicated to advancing cardiovascular medicine, with particular expertise in the management of difficult-to-treat hypertension. The center focuses on optimizing treatment strategies for patients with uncontrolled blood pressure through comprehensive clinical investigation and ambulatory blood pressure monitoring (ABPM).

  • Management of difficult-to-treat and resistant hypertension
  • Ambulatory blood pressure monitoring and assessment protocols
  • Comparative effectiveness of antihypertensive combination therapies

The research center employs sophisticated methodologies to evaluate triple single-pill combination (SPC) therapies and conducts comparative studies of various antihypertensive agents including eplerenone, spironolactone, and torasemide. Their work emphasizes evidence-based approaches to achieving optimal blood pressure control in challenging patient populations, contributing valuable insights into cardiovascular disease management.

Site Overview

assignment
1
connected trial
corporate_fare
2
sponsors
science
9
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
1
Total trials linked
Low Activity
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
2
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
1
Outperforms 1% of sites
public
Therapeutic diversity
1areas
Outperforms 1% of sites
groups
Sponsor diversity
2sponsors
Outperforms 44% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centrum Medyczno- Diagnostyczne Sp. z o.o.

Trial Sponsor Phase Status Start Date End Date
Evaluation of Eplerenone, Spironolactone, and Torasemide in the Management of Resistant Hypertension in Patients with Uncontrolled Blood PressureAgencja Badań Medycznych, Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut BadawczyPhase IRecruitingOct 2023

IMP list

lock Showing 1 of 9 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Amlodipine1Unknown2023-10-242023-10-24

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.